Twitter Facebook LinkedIn RSS
Welcome to the AUTM Global Technology Portal, where you can easily find the latest university technologies available for licensing worldwide.


AlzheimerΓÇÖs and Neurodegenerative Disease Treatment


Project TitleAlzheimerΓÇÖs and Neurodegenerative Disease Treatment
Track Code20110150
Short DescriptionGSH Analogs A pharmaceutical compound consisting of stable glutathione (GSH) analogs has been developed to treat Alzheimer's disease (AD) and other neurodegenerative disorders. The GSH analogs fulfill key roles of endogenous GSH and resist enzyme breakdown while acting as a substrate for the detoxifying enzyme glyoxalase-I. Decreases Glycation and Amyloid-beta Plaques The GSH analogs treat AD through two mechanisms. Amyloid-beta (A╬▓) plaques, a hallmark of AD and other neurodegenerative diseases, are caused by A╬▓ protein aggregation. A╬▓ aggregation is induced through glycation. Glyoxalase-I curbs glycation; but this process is dependent on GSH, which is severely depleted in an AD-affected brain. The new GSH analogs treat AD progression by restoring glyoxalase-I activity in the brain, which decreases glycation, and hampers glycation-induced A╬▓ aggregation, and in turn, plaque formation. Neutralizes Oxidative Stress The GSH analogs are able to pass through the blood-brain barrier to neutralize oxidative stress in the brain. Oxidative stress is a root cause of neurodegenerative disorders, as well as other diseases. Replicates Endogenous GSH Activity The new GSH analogs are the first compounds to replicate endogenous GSH activity while resisting breakdown. Other compounds which have tried to mimic the role of GSH failed because they were not resistant to breakdown. This treatment could be used in conjunction with other AD treatments, or used independently. This AD treatment can be used earlier than any other existing treatments. Hepatoprotective Qualities Separately, the GSH analogs were found to have hepatoprotective qualities. The analogs react directly with N-acetyl-p-benzoquinoneimine (NAPQI), a toxic by-product produced during acetaminophen metabolism. Using the GSH analogs in combination with acetaminophen could improve overall safety. The analogs could also act as a rescue treatment for acute acetaminophen overdose. BENEFITS AND FEATURES OF GSH ANALOGS COMPOUND: - Helps prevent harmful glycation and A╬▓ plaque formation - Treats AD earlier than other treatments - Can be used in combination with other treatments or independently - Antioxidant properties treats root cause of neurodegenerative disease - Has hepatoprotective qualities and could be used with acetaminophen Phase of Development In vitro and in vivo data available
Posted DateApr 23, 2015 12:51 PM


Potential Applications

Principal Investigator

Name : Swati More, Assistant Professor

Department : Center for Drug Design

Name : Robert Vince, Director

Department : Center for Drug Design

Contact Information

Name : Rebecca Gerber

Title : Technology Marketing Manager

Department : Office for Technology Commercialization

Email :

Phone :

Address :